INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 46m ago
HOUSE PTR5m ago
SEC 13F5m ago
ROBINHOOD CHAIN5m ago
Corporate insider
HJ

Haas Jason

DirectorCIK 0001883821

EDGAR filingsOpen in network
Disclosed transactions11
Buys / sells0 / 3
Max Insider Score50
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
HJ
Haas JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M—
6,138 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    LIGAND PHARMACEUTICALS INCDirector · Jun 9, 2026
43
HJ
Haas JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL
$2.09M
7,138 sh
Aug 12, 2026
Aug 14, 2026
traded Aug 12, 2026
+2d
SEC FORM 4

Evidence

23
HJ
Haas JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M$316K
6,138 sh
Aug 12, 2026Aug 14, 2026
traded Aug 12, 2026
+2dSEC FORM 4

Evidence

13
HJ
Haas JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M—
1,000 sh
Jun 12, 2026Jun 15, 2026
traded Jun 12, 2026
+3dSEC FORM 4

Evidence

20
HJ
Haas JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M$155K
3,000 sh
Jun 12, 2026Jun 15, 2026
traded Jun 12, 2026
+3dSEC FORM 4

Evidence

50
HJ
Haas JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL$886K
3,461 sh
Jun 12, 2026Jun 15, 2026
traded Jun 12, 2026
+3dSEC FORM 4

Evidence

16
HJ
Haas JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M$52K
1,000 sh
Jun 12, 2026Jun 15, 2026
traded Jun 12, 2026
+3dSEC FORM 4

Evidence

50
HJ
Haas JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Open-market sale
SELL$765K
3,000 sh
Jun 12, 2026Jun 15, 2026
traded Jun 12, 2026
+3dSEC FORM 4

Evidence

21
HJ
Haas JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Option exercise
M—
3,000 sh
Jun 12, 2026Jun 15, 2026
traded Jun 12, 2026
+3dSEC FORM 4

Evidence

13
HJ
Haas JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Grant or award
A—
836 sh
Jun 5, 2026Jun 9, 2026
traded Jun 5, 2026
+4dSEC FORM 4

Evidence

9
HJ
Haas JasonDirector
LGNDLIGAND PHARMACEUTICALS INC
Grant or award
A—
2,938 sh
Jun 5, 2026Jun 9, 2026
traded Jun 5, 2026
+4dSEC FORM 4

Evidence